Get the Stockscreener App
174.38
176.97%
111.42
Pre-market:
155.73
-18.65
-10.70%
Moderna Inc stock is traded at $174.38, with a volume of 193.10M.
It is up +176.97% in the last 24 hours and up +182.08% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$62.96
Open:
$116.02
24h Volume:
193.10M
Relative Volume:
20.61
Market Cap:
$69.62B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-21.41
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+173.88%
1M Performance:
+182.08%
6M Performance:
+250.87%
1Y Performance:
+524.79%
1-Day Range:
$114.46
$176.66
1-Week Range:
$60.82
$176.66
52-Week Range:
$22.28
$176.66
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
174.38 | 25.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
552.06 | 133.88B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
840.84 | 83.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,032.86 | 62.12B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
214.66 | 46.30B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna nearly triples in record S&P 500 move, but analyst sees more volatility ahead (MRNA:NASDAQ) - Seeking Alpha
5,814 Shares in Moderna, Inc. $MRNA Acquired by Commerzbank Aktiengesellschaft FI - MarketBeat
FDA approves Moderna's mRNA seasonal flu vaccineABC News - ABC News - Breaking News, Latest News and Videos
Moderna and Merck & Co are the stocks of the day on Wall Street - marketscreener.com
BlackRock Inc. Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
Moderna says melanoma vaccine trial shows "landmark moment" in treatment - CBS News
Moderna and Merck shares soar on mRNA cancer vaccine - Axios
Moderna pins hopes on mRNA ‘game-changer’ for cancer vaccines - ft.com
Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today? - Yahoo Finance
Healthcare Stocks After Hours: Moderna, Merck Cool Following Cancer Trial GainsPfizer (NYSE:PFE), Mode - Benzinga
Elon Musk Backs mRNA As Moderna's Stock Soars on Cancer Vaccine WinModerna (NASDAQ:MRNA) - Benzinga
Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough - Yahoo Finance
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough - Stocktwits
MRNA, BULL, BMNR, MSTR, MRK: 5 Trending Stocks TodayModerna (NASDAQ:MRNA) - Benzinga
Moderna's Most-Traded Call Options Up 54,000,000% on Cancer Vaccine Success | Options Income Daily - Moomoo
Moderna and Merck Revive mRNA Hopes With Melanoma Success - Moomoo
Doctors explain how Moderna's melanoma mRNA vaccine could fight deadliest form of skin cancer - CBS News
EXPERT REACTION: Moderna announce results of Phase 3 trial of personalized mRNA cancer vaccine - Scimex
US stock futures steady after tech slump; investors focus on Middle East tensions - Yahoo Finance
Why Moderna Stock Skyrocketed Today - The Motley Fool
Moderna stock surges as melanoma vaccine trial shows "landmark moment" - Yahoo Finance
Wall Street rises as yields ease, Moderna lifts healthcare stocks - Virginia Business
Wall St rises as yields ease, Moderna lifts healthcare stocks - marketscreener.com
Moderna’s skin cancer vaccine shows promise in trial - Semafor
Personalized mRNA cancer vaccine shows promise in extending life span in melanoma trial - ABC7 Bay Area
Moderna reaches "landmark moment" in Melanoma vaccine trial - CBS News
Moderna says its experimental vaccine prevented melanoma from returning or spreading - CBS News
Moderna (MRNA)’s Melanoma Vaccine Win: Big Opportunity, Bigger Expectations - Yahoo Finance
Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In FocusMerck & Co (NYSE:MRK) - Benzinga
Moderna Stock Soars on Cancer Vaccine Success - WSJ
Moderna vaccine shows promise in reducing melanoma recurrence - CBS News
Opinion | Moderna’s Road to a Cancer Vaccine - WSJ
Moderna Surges as Stocks Rise & Long-Term Yields Retreat | Closing Bell - marketscreener.com
Moderna Stock: The Cancer Vaccine Breakthrough Behind the Surge - Barron's
Moderna (MRNA) Soars 176.97% Following Promising Cancer Vaccine Trial Results - GuruFocus
Why Is Moderna (MRNA) Stock Rocketing Higher Today - Yahoo Finance
FirstFT: Moderna’s ‘landmark’ cancer treatment leads to share price surge - Financial Times
Morgan Stanley raises Moderna stock price target to $89 on platform strength - Investing.com
Moderna shares up 178% on success of melanoma vaccine trial - CNN
Stock Market Today, Aug. 19: Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data - Yahoo Finance
Merck (MRK) Stock Trades Up, Here Is Why - Yahoo Finance
Moderna, Inc. Stock Rises 44.2% in Six Months as Melanoma Trial Hits Targets - Cryptonews.net
Analysis-Moderna, Merck breakthrough could usher in wave of cancer vaccines - Yahoo! Finance Canada
Moderna (MRNA) Surges After Positive Vaccine Data Amid Market Volatility - GuruFocus
U.S. Stocks Up as Treasury Buybacks Calm Bond Yields; Moderna Surges - WSJ
Moderna, Merck breakthrough could usher in wave of cancer vaccines - marketscreener.com
MRNA Stock Rockets As FDA Clears New Flu Vaccine - StocksToTrade
Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data - Investopedia
‘Landmark’ trial shows mRNA therapy significantly cuts the odds of recurrent skin cancer - Scientific American
Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread - Al Jazeera
Moderna Stock Price Soars 177% on Melanoma Vaccine Success - Business Insider
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.02%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):